Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Dow
Express Scripts
McKinsey
Harvard Business School
AstraZeneca

Last Updated: November 28, 2022

Details for Patent: 7,943,621


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


Which drugs does patent 7,943,621 protect, and when does it expire?

Patent 7,943,621 protects VRAYLAR and is included in one NDA.

This patent has thirty-nine patent family members in thirty-three countries.

Summary for Patent: 7,943,621
Title:Salts of piperazine compounds as D.sub.3/D.sub.2 antagonists
Abstract: The present invention relates to novel monohydrochloride, dihydrochloride, monohydrobromide, maleate and methanesulphonate salts of trans 4-{2-[4-(2,3-dichlorophenyl)-piperazine-1-yl]-ethyl}-N,N-dimethylca- rbamoyl-cyclohexylamine and/or their hydrates and/or solvates. Moreover, the invention relates to the process for preparing the salts and their hydrates and/or solvates, to their use in the treatment and/or prevention of conditions which require modulation of dopamine receptor and to pharmaceutical compositions containing them.
Inventor(s): Czibula; Laszlo (Budapest, HU), Sebok; Ferenc (Mezokovacshaza, HU), Greiner; Istvan (Budapest, HU), Domany; Gyorgy (Obanya, HU), Csongor; Eva Againe (Budapest, HU)
Assignee: Richter Gedeon Nyrt. (Budapest, HU)
Application Number:12/118,437
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 7,943,621
Patent Claim Types:
see list of patent claims
Compound; Process; Composition;

Drugs Protected by US Patent 7,943,621

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Allergan VRAYLAR cariprazine hydrochloride CAPSULE;ORAL 204370-001 Sep 17, 2015 AB RX Yes No See Plans and Pricing See Plans and Pricing Y Y See Plans and Pricing
Allergan VRAYLAR cariprazine hydrochloride CAPSULE;ORAL 204370-002 Sep 17, 2015 AB RX Yes No See Plans and Pricing See Plans and Pricing Y Y See Plans and Pricing
Allergan VRAYLAR cariprazine hydrochloride CAPSULE;ORAL 204370-003 Sep 17, 2015 AB RX Yes No See Plans and Pricing See Plans and Pricing Y Y See Plans and Pricing
Allergan VRAYLAR cariprazine hydrochloride CAPSULE;ORAL 204370-004 Sep 17, 2015 AB RX Yes Yes See Plans and Pricing See Plans and Pricing Y Y See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 7,943,621

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2008249772 See Plans and Pricing
Brazil PI0811199 See Plans and Pricing
Canada 2684404 See Plans and Pricing
China 101679315 See Plans and Pricing
Colombia 6241112 See Plans and Pricing
Cyprus 1119076 See Plans and Pricing
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
AstraZeneca
McKinsey
Mallinckrodt
Boehringer Ingelheim
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.